322 related articles for article (PubMed ID: 31676244)
1. Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.
Pion SD; Nana-Djeunga H; Niamsi-Emalio Y; Chesnais CB; Deléglise H; Mackenzie C; Stolk W; Fletcher DA; Klion AD; Nutman TB; Boussinesq M; Kamgno J
Lancet Infect Dis; 2020 Jan; 20(1):102-109. PubMed ID: 31676244
[TBL] [Abstract][Full Text] [Related]
2. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.
Kamgno J; Pion SD; Chesnais CB; Bakalar MH; D'Ambrosio MV; Mackenzie CD; Nana-Djeunga HC; Gounoue-Kamkumo R; Njitchouang GR; Nwane P; Tchatchueng-Mbouga JB; Wanji S; Stolk WA; Fletcher DA; Klion AD; Nutman TB; Boussinesq M
N Engl J Med; 2017 Nov; 377(21):2044-2052. PubMed ID: 29116890
[TBL] [Abstract][Full Text] [Related]
3. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
[TBL] [Abstract][Full Text] [Related]
4. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa.
Wanji S; Chounna Ndongmo WP; Fombad FF; Kengne-Ouafo JA; Njouendou AJ; Longang Tchounkeu YF; Koudou B; Bockarie M; Fobi G; Roungou JB; Enyong PA
PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006750. PubMed ID: 30226900
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Onchocerciasis Elimination Using a "Test-and-not-treat" Strategy in Loa loa Co-endemic Areas.
Blok DJ; Kamgno J; Pion SD; Nana-Djeunga HC; Niamsi-Emalio Y; Chesnais CB; Mackenzie CD; Klion AD; Fletcher DA; Nutman TB; de Vlas SJ; Boussinesq M; Stolk WA
Clin Infect Dis; 2021 Jun; 72(12):e1047-e1055. PubMed ID: 33289025
[TBL] [Abstract][Full Text] [Related]
6. A Test-and-Not-Treat Strategy for Onchocerciasis Elimination in Loa loa-coendemic Areas: Cost Analysis of a Pilot in the Soa Health District, Cameroon.
Lenk EJ; Moungui HC; Boussinesq M; Kamgno J; Nana-Djeunga HC; Fitzpatrick C; Peultier AMM; Klion AD; Fletcher DA; Nutman TB; Pion SD; Niamsi-Emalio Y; Redekop WK; Severens JL; Stolk WA
Clin Infect Dis; 2020 Apr; 70(8):1628-1635. PubMed ID: 31165855
[TBL] [Abstract][Full Text] [Related]
7. Structure of the microfilarial reservoir of Loa loa in the human host and its implications for monitoring the progr,ammes of Community-Directed Treatment with Ivermectin carried out in Africa.
Pion DS; Gardon J; Kamgno J; Gardon-Wendel N; Chippaux JP; Boussinesq M
Parasitology; 2004 Nov; 129(Pt 5):613-26. PubMed ID: 15552406
[TBL] [Abstract][Full Text] [Related]
8. Geostatistical modelling enables efficient safety assessment for mass drug administration with ivermectin in Loa loa endemic areas through a combined antibody and LoaScope testing strategy for elimination of onchocerciasis.
Johnson O; Giorgi E; Fronterrè C; Amoah B; Atsame J; Ella SN; Biamonte M; Ogoussan K; Hundley L; Gass K; Diggle PJ
PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010189. PubMed ID: 35139080
[TBL] [Abstract][Full Text] [Related]
9. Loiasis is endemic in the Ndikinimeki Health District (Centre Region, Cameroon) but does not represent a hindrance to onchocerciasis elimination.
Sumo L; Ntonifor NH; Afor AR; Bopda J; Bamou Heumou R; Ondoua Nganjou GS; Nana Djeunga HC
Acta Trop; 2022 Jan; 225():106218. PubMed ID: 34755644
[TBL] [Abstract][Full Text] [Related]
10. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial.
Turner JD; Tendongfor N; Esum M; Johnston KL; Langley RS; Ford L; Faragher B; Specht S; Mand S; Hoerauf A; Enyong P; Wanji S; Taylor MJ
PLoS Negl Trop Dis; 2010 Apr; 4(4):e660. PubMed ID: 20405054
[TBL] [Abstract][Full Text] [Related]
11. Evaluating post-treatment Loa loa microfilarial densities to classify serious adverse events caused by ivermectin: a retrospective analysis.
Boullé C; Chesnais CB; Kamgno J; Gardon J; Chippaux JP; Ranque S; Garcia A; Pion SD; Boussinesq M
Lancet Microbe; 2023 Feb; 4(2):e93-e101. PubMed ID: 36646105
[TBL] [Abstract][Full Text] [Related]
12. Co-endemicity of loiasis and onchocerciasis in the South West Province of Cameroon: implications for mass treatment with ivermectin.
Esum M; Wanji S; Tendongfor N; Enyong P
Trans R Soc Trop Med Hyg; 2001; 95(6):673-6. PubMed ID: 11816443
[TBL] [Abstract][Full Text] [Related]
13. Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon.
Boussinesq M; Gardon J; Kamgno J; Pion SD; Gardon-Wendel N; Chippaux JP
Ann Trop Med Parasitol; 2001 Jul; 95(5):495-507. PubMed ID: 11487371
[TBL] [Abstract][Full Text] [Related]
14. Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.
Wanji S; Tendongfor N; Esum M; Yundze SS; Taylor MJ; Enyong P
Filaria J; 2005 Apr; 4(1):2. PubMed ID: 15817124
[TBL] [Abstract][Full Text] [Related]
15. [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Ducorps M; Gardon-Wendel N; Ranque S; Ndong W; Boussinesq M; Gardon J; Schneider D; Chippaux JP
Bull Soc Pathol Exot; 1995; 88(3):105-12. PubMed ID: 8555762
[TBL] [Abstract][Full Text] [Related]
16. Co-endemicity of loiasis and onchocerciasis in rain forest communities in southwestern Nigeria.
Ojurongbe O; Akindele AA; Adeleke MA; Oyedeji MO; Adedokun SA; Ojo JF; Akinleye CA; Bolaji OS; Adefioye OA; Adeyeba OA
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003633. PubMed ID: 25812086
[TBL] [Abstract][Full Text] [Related]
17. Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa.
Kamgno J; Nana-Djeunga HC; Pion SD; Chesnais CB; Klion AD; Mackenzie CD; Nutman TB; Boussinesq M
Int Health; 2018 Mar; 10(suppl_1):i49-i53. PubMed ID: 29471340
[TBL] [Abstract][Full Text] [Related]
18. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.
Twum-Danso NA; Meredith SE
Trop Med Int Health; 2003 Sep; 8(9):820-31. PubMed ID: 12950668
[TBL] [Abstract][Full Text] [Related]
19. Excess mortality associated with loiasis: a retrospective population-based cohort study.
Chesnais CB; Takougang I; Paguélé M; Pion SD; Boussinesq M
Lancet Infect Dis; 2017 Jan; 17(1):108-116. PubMed ID: 27777031
[TBL] [Abstract][Full Text] [Related]
20. Individual risk of post-ivermectin serious adverse events in subjects infected with
Chesnais CB; Pion SD; Boullé C; Gardon J; Gardon-Wendel N; Fokom-Domgue J; Kamgno J; Boussinesq M
EClinicalMedicine; 2020 Nov; 28():100582. PubMed ID: 33294807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
